Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Nivolumab ± ipilimumab in pts with advanced (adv)/metastatic chemotherapy-refractory (CTx-R) gastric (G), esophageal (E), or gastroesophageal junction (GEJ) cancer: CheckMate 032 study
29 března, 2021 10:03 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4014 Citation: J Clin Oncol 35,...
KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer
29 března, 2021 9:57 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Noncolorectal) Cancer Abstract number: 4003 Citation: J Clin Oncol 35,...
Primary (1°) tumor location as an independent prognostic marker from molecular features for overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB / SWOG 80405 (Alliance)
29 března, 2021 9:47 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3503 Citation: J Clin Oncol 35,...
Risk-Based Approach to Chemotherapy Duration Recommended for Stage III Colon Cancer
29 března, 2021 9:42 pmJune 4, 2017 In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly...
ONCOLOGICAL BENEFIT OF PARENCHYMA-PRESERVING HEPATECTOMY FOR COLORECTAL LIVER METASTASIS
29 března, 2021 9:39 pmMeeting: 2016 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3526 Citation: J Clin Oncol 34,...
SOMATIC DNA MUTATIONS, MSI STATUS, MUTATIONAL LOAD (ML): ASSOCIATION WITH OVERALL SURVIVAL (OS) IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) OF CALGB/SWOG 80405 (ALLIANCE)
29 března, 2021 9:33 pmMeeting: 2017 ASCO Annual Meeting Track: Gastrointestinal (Colorectal) Cancer Abstract number: 3504 Citation: J Clin Oncol 35,...
Post-Surgery Capecitabine ‘Should Become Standard of Care’ in Biliary Tract Cancers
29 března, 2021 9:26 pmJune 4, 2017 In a study of 447 patients with biliary tract cancers, capecitabine improved overall survival (OS) when...
VYBRANÉ NOVINKY ZAMĚŘENÉ NA ZHOUBNÉ NÁDORY ZAŽÍVACÍHO TRAKTU
29 března, 2021 9:23 pmAdjuvantní chemoterapie karcinomu tlustého střeva (CC) – čas ke změně Prospektivní analýza šesti adjuvantních klinických studií je odrazovým můstkem ke změně...
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
12 března, 2021 7:36 pmMeeting: 2018 ASCO Annual Meeting Track: Melanoma/Skin Cancers Abstract number: 9504 Authors: Reinhard Dummer, Paolo Antonio Ascierto,...
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study
12 března, 2021 7:33 pmMeeting: 2018 ASCO Annual Meeting Track: Patient and Survivor Care Abstract number: 10 038 Authors: Francesco De...